Africa: IP in Africa: A little different

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Africa: IP in Africa: A little different

An article that recently appeared in the South African news publication Daily Maverick, Intellectual property for the 21st century economy, reminds us that, notwithstanding the increasing homogenisation of IP laws, parts of the developing world are yet to be totally convinced that IP is the best way of ensuring innovation and progress.

The article was written by renowned economist Joseph Stiglitz. He comes right to the point when he says this: 'Developing countries are increasingly pushing back against the intellectual property regime foisted on them by advanced economies over the last 30 years… they are right to do so because what matters is not only the production of knowledge, but also that it is used in ways that put the health and well-being of people ahead of corporate profits.'

According to Stiglitz, the pushback is being led by South Africa, India and Brazil, and the focus is medicines. Although South Africa has in the past felt the 'full legal might of the global pharmaceutical industry', it is in the process of finalising an IP policy that expands access to medicines. The South African government 'is right, and other developing and emerging economies should follow in its footsteps.'

Stiglitz is critical of IP: it was wrong to impose a 'one-size-fits-all' policy; the standards imposed by the developed world are not designed to maximise progress and innovation, but rather corporate profits; the institutions and laws protecting knowledge are increasingly inadequate to govern global economic activity, and poorly suited to the needs of developing countries; patents may encourage research, but the sheer number of patents now stifles innovation; much of the research that is taking place is aimed at extending protection rather than creating new products. The IP regime has, says Stiglitz, erected barriers to the use of knowledge, and this is not sustainable.

Stiglitz says that the 21st century economy will differ from that of the 20th century in two major ways – the economic weight of countries like South Africa, Brazil and India will increase, and the economy of ideas, knowledge and information will become increasingly important. Developing countries should be looking at alternatives to patents for financing research, including centralised bodies like national health institutes, tax credits and prizes.

IP owners in the developed world, as well as their advisors, would do well to bear these philosophical differences in mind

Wayne Meiring


Spoor & Fisher Jersey Africa House, Castle Street St Helier, Jersey JE4 9TW Channel Islands Tel: +44 1534 838000 Fax: +44 1534 838001

info@spoor.co.uk

www.spoor.com

more from across site and SHARED ros bottom lb

More from across our site

New platform, which covers SEPs covering the Wi-Fi 6 and Wi-Fi 7 standards, includes 10 patent owners
The Texas-based IP litigation hires take King & Spalding’s partner appointments from pre-merger Winston & Strawn up to 12 this year
Sunny Su explains how her team overcame challenges with orchard evidence collection to secure a favourable plant variety decision from China’s top court
Flexible working firm continues trajectory from 2025 with appointment of Matthew Grant and Letao Qin
Anousha Davies, associate and trademark attorney at Birketts, unpicks how the university’s reputation enabled it to see off a proposed trademark for ‘Cambridge Rowing’
IP lawyers, who say they are encouraging clients to build up ‘tariff resilience’, should treat the risks posed by recent orders as a core consideration in cross-border licensing
Regulatory changes and damages risks are prompting Canadian firms and clients to opt for settlements in generic and biosimilar cases
News of Via Licensing Alliance adding two new members and Nokia’s proposal to extend interim licences to Warner Bros Discovery and Paramount were also among the top talking points
A new claim filed by Ericsson, and a request for access to documents, were also among recent developments
Cooley and Stikeman Elliott advised 35Pharma on the deal, which will allow GSK to get its hands on S235, an investigational medicine for pulmonary hypertension
Gift this article